ACE-232

· Acerand Therapeutics (Hong Kong) Limited

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ACE-232, covering 2026-04-09 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]